Lantheus Holdings, Inc. · NASDAQ:LNTH

Lantheus — Q2 2023 Earnings Presentation

33 slides from Lantheus's earnings presentation, Aug 3, 2023

Slide 2: Presenters and Agenda
Mary Anne Heino Paul Blanchfield Bob Marshall Mark Kinarney CEO President CFO and Treasurer Vice President, Investor Relations Highlights & Business Update Operational Update Financial Update Closing Remarks Q&A © 2023 Lantheus. All rights reserved. 2
Slide 3: Safe Harbor Statements
Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe har
Slide 5: Lantheus, the Leading Radiopharmaceutical-Focused Company
Lantheus, the Leading Radiopharmaceutical-Focused Company Advancing our purpose to FIND. FIGHT. #1 PSMA PET UNIQUELY POSITIONED FOLLOW. Imaging Agent with sustainable to lead and shape this industry going forward disease to deliver better competitive advantages1 patient outcomes RECOGNIZED LEADERSHI
Slide 6: Renaissance in Radiopharmaceuticals
Renaissance in Radiopharmaceuticals THE NEXT BIG DISRUPTER becoming mainstream diagnostics & therapies EXPANDING OUR PIPELINE2 LATE-STAGE EARLIER-STAGE Global Radiopharmaceutical Market1 USD Billions THERAPEUTICS ASSETS 35 Therapeutics PNT20023 MK-6240 Diagnostics Prostate cancer F18 PET imaging age
Slide 7: PYLARIFY, the #1 leader in U.S. PSMA PET imaging market
PYLARIFY POSLUMA FDA-APPROVED PSMA PET Imaging Agents: Distinct F18 Products: New • Piflufolastat F-18 (PYLARIFY®) Chemical Entities • Flotufolastat F-18 (POSLUMA®) Gallium Products: Ga-68- • Gozetotide (Illuccix®) PSMA-11 • PSMA-11 (UCLA) Based Entities • PSMA-11 (UCSF) • Gozetotide (LOCAMETZ®) PYL
Slide 9: PYLARIFY 2Q 2023 Net Sales
>200,000 PSMA PET scans $210.5M with PYLARIFY since launch 2Q 2023 Net Sales PYLARIFY delivers a best-in-class patient & +61.7% customer experience growth with sustainable competitive year over year advantages © 2023 Lantheus. All rights reserved. 9
Slide 10: PYLARIFY is Clinically & Commercially Differentiated
PYLARIFY is Clinically & Commercially Differentiated Clinical Differentiators Commercial Differentiators Robust Change F18- Largest Multi-Partner PET Longer in Intended High Inter- and Broad Related Dedicated Manufacturing Half-Life5,6 Patient Intra-Reader Payer Image Commercial Facility (PMF) Distr
Slide 11: DEFINITY 2Q 2023 Net Sales
Drivers of $70.5M Success 2Q 2023 Net Sales • Clinical Differentiation • Distribution Model • Supporting Data & +13.2% growth Publications • Dedicated Sales Team year over year DEFINITY is the clear market leader in the U.S. Ultrasound Enhancing Agent market © 2023 Lantheus. All rights reserved. 11
Slide 12: Leveraging Our Leadership in Radiopharmaceuticals to Grow Our Portfolio
Leveraging Our Leadership in Radiopharmaceuticals to Grow Our Portfolio SPLASH Phase 3 Trial Designed to evaluate the efficacy and safety of lutetium-177 PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following PNT2002 treatment with an androgen receptor
Slide 13: Progressing our Radiopharmaceutical Pipeline
Progressing our Radiopharmaceutical Pipeline MK-6240 LNTH-1363S Novel, clinical-stage, second FAP Alpha-Targeted, Copper-64 generation PET imaging agent for Labelled PET imaging agent Alzheimer’s disease POTENTIAL TO BECOME BIOMARKER FOR USED AS BIOMARKER IN PRECISION MEDICINE IN CANCER MORE THAN 60
Slide 15: 2Q 2023 Financial Highlights
2Q 2023 Financial Highlights1 Revenue Adjusted EPS1 USD Millions USD +$98.0 +$0.66 +43.8% +73.8% 321.7 1.54 223.7 0.89 2Q 2022 2Q 2023 2Q 2022 2Q 2023 Cash and Cash Equivalents as of June 30, 2023: $414.1M 1. See slide 28 for reconciliations of GAAP to non-GAAP financials; certain amounts may be sub
Slide 16: 2Q 2023 Revenue Highlights
2Q 2023 Revenue Highlights Reported: WW $321.7M, +43.8% growth YoY USD in millions, YoY Quarterly Growth KEY DRIVERS $12.8 (+134.4%) • Meaningful customer adoption, amidst competition, PYLARIFY driven by increased investment in promotional activity $21.6 (+11.1%) $70.5 (+13.2%) DEFINITY • Increase i
Slide 17: 2Q 2023 Operating Expense Highlights
2Q 2023 Operating Expense Highlights1 2Q 2023 Adjusted Operating Expense: 22.9% of Net Revenue, 345 bps Favorable YoY USD in millions Adjusted Operating Profit Adjusted Net Income Adjusted OPEX +$61.5 +$46.7 Sales & Marketing +69.4% +74.3% +$14.7 +25.0% 150.1 109.6 73.8 88.6 62.9 General 59.0 & Admi
Slide 18: Strong Resources Provide Financial Flexibility
Strong Resources Provide Financial Flexibility1 USD Millions Cash Flow Summary Free Cash Flow Resources Three Months Ending June 30 (2Q 2023) $M 2022 20233 $111.2 Cash provided $68.3 DECREASE $414.1M by (used in) $72.6 $(32.3) operations CASH ON HAND2 Cash used in -$43.0 ($4.3) ($20.7) investing Cas
Slide 19: 3Q 2023 and Updated FY 2023 Financial Guidance
3Q 2023 and Updated FY 2023 Financial Guidance1 The Company guidance for the third quarter and full year 2023 is as follows: Revenue $310M - $315M 3Q 2023 Adjusted Fully Diluted EPS $1.30 - $1.35 Prior Revenue $1.23B - $1.27B FY Current Revenue $1.245B - $1.27B 2023 Prior Adjusted Fully Diluted EPS2
Slide 21: Lantheus, the Leading Radiopharmaceutical-Focused Company: 2Q 2023 Results
Lantheus, the Leading Radiopharmaceutical-Focused Company 2Q 2023 Results Proven Track Record of Success 65 years of • Solid quarter with revenue up 44% year over year Radiopharmaceutical Expertise • PYLARIFY is clinically and commercially differentiated PSMA PET Imaging Agent #1 with sustainable co
Slide 28: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures (in thousands, except per share data – unaudited) © 2023 Lantheus. All rights reserved. 28
Slide 33: Proven Management Team with Deep Industry Expertise
Proven Management Team with Deep Industry Expertise Mary Anne Heino Paul Blanchfield Robert Marshall Chief Executive Officer President Chief Financial Officer and 2013 2020 Treasurer 2018 Previously: Janssen, Centocor, Inc, Previously: Takeda, Shire, Previously: Zimmerbiomet, Angleini, Labopharm McK

Lantheus Holdings — Q2 2023 Earnings Presentation on 6ix

Lantheus — Q2 2023 Earnings Presentation

Slide 1: Second Quarter 2023 Results

Slide 2: Presenters and Agenda

Slide 3: Safe Harbor Statements

Slide 4: Agenda

Slide 5: Lantheus, the Leading Radiopharmaceutical-Focused Company

Slide 6: Renaissance in Radiopharmaceuticals

Slide 7: PYLARIFY, the #1 leader in U.S. PSMA PET imaging market

Slide 8: Agenda

Slide 9: PYLARIFY 2Q 2023 Net Sales

Slide 10: PYLARIFY is Clinically & Commercially Differentiated

Slide 11: DEFINITY 2Q 2023 Net Sales

Slide 12: Leveraging Our Leadership in Radiopharmaceuticals to Grow Our Portfolio

Slide 13: Progressing our Radiopharmaceutical Pipeline

Slide 14: Agenda

Slide 15: 2Q 2023 Financial Highlights

Slide 16: 2Q 2023 Revenue Highlights

Slide 17: 2Q 2023 Operating Expense Highlights

Slide 18: Strong Resources Provide Financial Flexibility

Slide 19: 3Q 2023 and Updated FY 2023 Financial Guidance

Slide 20: Agenda

Slide 21: Lantheus, the Leading Radiopharmaceutical-Focused Company: 2Q 2023 Results

Slide 22: Agenda

Slide 23: Appendix

Slide 24: Condensed Consolidated Statement of Operations – 2Q 2023

Slide 25: As Adjusted Condensed Consolidated Statement of Operations – 2Q 2023

Slide 26: Condensed Consolidated Statement of Operations – FY 2Q 2023

Slide 27: As Adjusted Condensed Consolidated Statement of Operations – FY 2Q 2023

Slide 28: Reconciliation of GAAP to Non-GAAP Financial Measures

Slide 29: Consolidated Statement of Operations

Slide 30: Consolidated Segment Revenues Analysis

Slide 31: Reconciliation of Free Cash Flow

Slide 32: Condensed Consolidated Balance Sheet

Slide 33: Proven Management Team with Deep Industry Expertise